Anthracycline-induced cardiotoxicity: Prospective cohort study from Pakistan

BMJ Open

Volumn 3, Issue 11, 2013, Pages

  Shaikh, Abdul Sattar ^a   Saleem, Ali Faisal ^a   Mohsin, Shazia Samad ^a   Alam, Muhammad Matloob ^a   Ahmed, Mehnaz Atiq ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DOXORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PAKISTAN; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SYSTOLIC DYSFUNCTION; TERTIARY HEALTH CARE; TRISOMY 21;

EID: 84890346188     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003663     Document Type: Article

References (35)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5.
2. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008;94:525-33.
3. Monsuez JJ, Charniot JC, Vignat N, et al. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010;144:3-15.
4. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
5. Bu'Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995;73:340-50.
6. Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007;7:61-6.
7. Giantris A, Abdurrahman L, Hinkle A, et al. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol 1998;27:53-68.
8. Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002;13:503-12.
9. Keizer HG, Pinedo HM, Schuurhuis GJ, et al. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990;47:219-31.
10. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 1998;25:10-14.
11. Bu'Lock FA, Mott MG, Martin RP. Left ventricular diastolic function in children measured by Doppler echocardiography: normal values and relation with growth. Br Heart J 1995;73:334-9.
12. Ganame J, Claus P, Uyttebroeck A, et al . Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J Am Soc Echocardiogr 2007;20:1351-8.
13. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992;89:942-9.
14. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30:1527-33.
15. Ommen SR, Nishimura RA, Appleton CP, et al . Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler- catheterization study. Circulation 2000;102:1788-94.
16. Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997;30:474-80.
17. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function - a study in normal and dilated cardiomyopathy. J Cardiol 1995;26:357-66.
18. Nousiainen T, Jantunen E, Vanninen E, et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002;86:1697-700.
19. Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7:141-6.
20. Gatta G, Capocaccia R, Coleman MP, et al. Childhood cancer survival in Europe and the United States. Cancer 2002;95:1767-72.
21. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-17.
22. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629-36.
23. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62.
24. Iarussi D, Galderisi M, Ratti G, et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol 2001;24:663-9.
25. Erdogan D, Yucel H, Alanoglu EG, et al. Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy? Turk Kardiyol Dern Ars 2011;39:646-53.
26. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62.
27. Belham M, Kruger A, Mepham S, et al. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007;9:409-14.
28. Roodpeyma S, Moussavi F, Kamali Z. Late cardiotoxic effects of anthracycline chemotherapy in childhood malignancies. J Pak Med Assoc 2008;58:683-7.
29. Velensek V, Mazic U, Krzisnik C, et al . Cardiac damage after treatment of childhood cancer: a long-term follow-up. BMC Cancer 2008;8:141.
30. Stoddard MF, Seeger J, Liddell NE, et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62-9.
31. Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58.
32. Godoy LY, Fukushige J, Igarashi H, et al. Anthracycline-induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn 1997;39:188-93.
33. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002;4:235-42.
34. Galderisi M, Marra F, Esposito R, et al. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007;5:4.
35. Lipshultz SE, Landy DC, Lopez-Mitnik G, et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012;30:1050-7.